baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Veloxis Pharmaceuticals A/S/ DK0060048148 /

24/02/2020 00:00:00	Chg. -	Volume	Bid-	Ask-	High	Low
5.980DKK	-	507,488 Turnover: -	-Bid Size: -	-Ask Size: -	5.990	5.980

GlobeNewswire 18:15 OSE Immunotherapeutics Provides Business and Corporate Update

GlobeNewswire 22/05 OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treat...

GlobeNewswire 16/04 OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of C...

GlobeNewswire 02/04 OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1...

GlobeNewswire 21/03/2022 OSE Immunotherapeutics Receives First Notice of Allowance for a US Patent Covering Anti-PD1 Monoclon...

GlobeNewswire 16/03/2022 OSE Immunotherapeutics Provides Positive Long Term Memory Responses with CoVepiT, its T Lymphocyte M...

GlobeNewswire 09/03/2022 Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clini...

GlobeNewswire 18/02/2022 OSE Immunotherapeutics Announces Appointment of Alexandre Lebeaut as an Independent Member of the Bo...

GlobeNewswire 17/02/2022 OSE Immunotherapeutics is Pleased to Announce that Veloxis Pharmaceuticals, Inc., its Partner in Tra...

GlobeNewswire 01/02/2022 Transfer of OSE Immunotherapeutics’ Shares from Compartment C to Compartment B of Euronext Paris fro...

GlobeNewswire 31/01/2022 OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obt...

GlobeNewswire 27/12/2021 Revolo Biotherapeutics Announces the Appointment of Tunde Otulana, M.D., to its Board of Directors

GlobeNewswire 21/09/2021 OSE Immunotherapeutics Announces H1 2021 Results and Provides a Corporate Update

GlobeNewswire 08/09/2021 Xenikos Secures €40 Million in Convertible Debt Financing, Veloxis Pharmaceuticals Joins as Strategi...

GlobeNewswire 26/04/2021 OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, M...

GlobeNewswire 31/03/2020 Rockwell Medical, Inc. Appoints Pharmaceutical Industry Leader Robert S. Radie to Board of Directors

GlobeNewswire 05/12/2019 Innovative Cellular Therapeutics Strengthens Executive Leadership Team with Appointment of Morten Ma...

GlobeNewswire 21/06/2018 Bioavailability Enhancement Technologies and Services Market, 2030

GlobeNewswire 05/06/2017 Veloxis Pharmaceuticals A/S and Endo Ventures Limited Jointly Announce Agreement for Paladin Labs In...

GlobeNewswire 20/12/2016 Veloxis Pharmaceuticals Announces Financial Calendar for 2017

GlobeNewswire 13/03/2014 DOUBLE-DIGIT GROWTH AND INTERNATIONAL EXPANSION FOR THE CHIESI GROUP

Veloxis Pharmaceuticals A/S/ DK0060048148 /

If you wish to receive reply to your feedback, please provide your email address.